Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DNA Stock Forecast 2025-2026
$8.58
Current Price
$502.20M
Market Cap
Buy 1
Hold 1
Sell 3
Wall St Analyst Ratings
Distance to DNA Price Targets
+39.9%
To High Target of $12.00
+4.9%
To Median Target of $9.00
-30.1%
To Low Target of $6.00
DNA Price Momentum
-7.6%
1 Week Change
+6.1%
1 Month Change
-49.0%
1 Year Change
-12.6%
Year-to-Date Change
-53.4%
From 52W High of $18.40
+71.6%
From 52W Low of $5.00
📊 TOP ANALYST CALLS
Did DNA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Ginkgo Bioworks is one of their latest high-conviction picks.
Latest DNA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, DNA has a bearish consensus with a median price target of $9.00 (ranging from $6.00 to $12.00). The overall analyst rating is Hold (5.2/10). Currently trading at $8.58, the median forecast implies a 4.9% upside. This outlook is supported by 1 Buy, 1 Hold, and 3 Sell ratings.
Conversely, the most conservative target is provided by Gaurav Goparaju at Berenberg, suggesting a 30.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DNA Analyst Ratings
1
Buy
1
Hold
3
Sell
DNA Price Target Range
Low
$6.00
Average
$9.00
High
$12.00
Current: $8.58
Latest DNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 20, 2024 | TD Cowen | Brendan Smith | Buy | Maintains | $10.00 |
| Aug 23, 2024 | BTIG | Mark Massaro | Sell | Maintains | $7.00 |
| Jul 9, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $0.30 |
| Jun 26, 2024 | BTIG | Mark Massaro | Sell | Maintains | $0.20 |
| May 15, 2024 | BTIG | Mark Massaro | Sell | Downgrade | $0.00 |
| May 15, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $1.00 |
| May 10, 2024 | William Blair | Matt Larew | Underperform | Downgrade | $0.00 |
| Mar 1, 2024 | TD Cowen | Steven Mah | Outperform | Maintains | $3.00 |
| Jan 23, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $1.10 |
| Jan 22, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $1.10 |
| Nov 15, 2023 | Raymond James | Rahul Sarugaser | Market Perform | Downgrade | $2.50 |
| Nov 14, 2023 | Raymond James | Rahul Sarugaser | Market Perform | Downgrade | $2.50 |
| Nov 9, 2023 | BTIG | Mark Massaro | Neutral | Downgrade | $0.00 |
| Jun 5, 2023 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $1.25 |
| Jun 2, 2023 | Goldman Sachs | Matthew Sykes | Sell | Downgrade | $1.25 |
| May 11, 2023 | William Blair | Matt Larew | Market Perform | Downgrade | $0.00 |
| Nov 29, 2022 | Berenberg | Gaurav Goparaju | Buy | Initiates | $6.00 |
| Oct 4, 2022 | Morgan Stanley | Tejas Savant | Equal-Weight | Initiates | $5.00 |
| Aug 16, 2022 | BTIG | Mark Massaro | Buy | Maintains | $6.00 |
| Aug 16, 2022 | Raymond James | Rahul Sarugaser | Outperform | Maintains | $14.50 |
Ginkgo Bioworks Holdings Inc. (DNA) Competitors
The following stocks are similar to Ginkgo Bioworks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ginkgo Bioworks Holdings Inc. (DNA) Financial Data
Ginkgo Bioworks Holdings Inc. has a market capitalization of $502.20M with a P/E ratio of -0.8x. The company generates $237.42M in trailing twelve-month revenue with a -198.8% profit margin.
Revenue growth is +27.3% quarter-over-quarter, while maintaining an operating margin of -182.1% and return on equity of -57.8%.
Valuation Metrics
Market Cap
$502.20M
Enterprise Value
$418.09M
P/E Ratio
-0.8x
PEG Ratio
-1.1x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+27.3%
Gross Margin
+75.1%
Operating Margin
-182.1%
Net Margin
-198.8%
EPS Growth
+27.3%
Financial Health
Cash/Price Ratio
+102.9%
Current Ratio
4.9x
Debt/Equity
67.1x
ROE
-57.8%
ROA
-17.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ginkgo Bioworks Holdings Inc. (DNA) Business Model
About Ginkgo Bioworks Holdings Inc.
What They Do
Designs and grows bespoke organisms using synthetic biology.
Business Model
Ginkgo Bioworks operates a unique 'cell programming' platform that enables the engineering of custom organisms for various industries, generating revenue through partnerships and collaborations with clients seeking innovative biological solutions.
Additional Information
Based in Boston, Massachusetts, Ginkgo is a leader in synthetic biology, aiming to transform the use of biological resources and contribute to a sustainable bioeconomy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
834
CEO
Dr. Jason Kelly Ph.D.
Country
United States
IPO Year
2021
Website
www.ginkgo.bioGinkgo Bioworks Holdings Inc. (DNA) Latest News & Analysis
Latest News
Quick Summary
Ginkgo Bioworks' CFO Mark Dmytruk will resign on May 30, 2025. Steven Coen, CPA, will succeed him as CFO.
Why It Matters
Leadership changes can impact a company's strategic direction and investor confidence. A new CFO may bring different financial strategies, affecting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Twist Bioscience and Ginkgo Bioworks have renegotiated their collaboration, signing a three-year agreement worth $15 million, updating a prior contract from 2022.
Why It Matters
The updated collaboration between Twist Bioscience and Ginkgo Bioworks signals a strategic partnership in biotech, potentially enhancing growth prospects and market positioning for both companies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Ginkgo Bioworks will hold its Q1 2025 results conference call on May 6, 2025, at 5:00 PM ET, featuring CEO Jason Kelly and CFO Mark Dmytruk.
Why It Matters
Ginkgo Bioworks' Q1 2025 results may indicate financial health and growth potential, influencing stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Ginkgo Bioworks reported progress on its $250 million cost savings target and secured a $29 million contract from ARPA-H for essential medicine manufacturing using wheat germ systems.
Why It Matters
Ginkgo's restructuring and cost savings target signal improved financial health, while the ARPA-H contract highlights growth potential in essential medicine manufacturing, boosting investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Ginkgo Bioworks reported a quarterly loss of $1.58 per share, exceeding the Zacks estimate of $1.23, but an improvement from a loss of $3.20 per share a year prior.
Why It Matters
Ginkgo Bioworks' larger-than-expected loss signals potential operational challenges, raising concerns about profitability and future growth, impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Ginkgo Bioworks will host a Q&A session on May 6, 2025, at 5:30 p.m. ET to discuss Q1 2025 business performance. Details will be available on their investor relations website.
Why It Matters
Ginkgo Bioworks is set to review Q1 2025 performance, providing insights into its growth and strategy, which can influence investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DNA Stock
What is Ginkgo Bioworks Holdings Inc.'s (DNA) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, Ginkgo Bioworks Holdings Inc. (DNA) has a median price target of $9.00. The highest price target is $12.00 and the lowest is $6.00.
Is DNA stock a good investment in 2025?
According to current analyst ratings, DNA has 1 Buy ratings, 1 Hold ratings, and 3 Sell ratings. The stock is currently trading at $8.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DNA stock?
Wall Street analysts predict DNA stock could reach $9.00 in the next 12 months. This represents a 4.9% increase from the current price of $8.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ginkgo Bioworks Holdings Inc.'s business model?
Ginkgo Bioworks operates a unique 'cell programming' platform that enables the engineering of custom organisms for various industries, generating revenue through partnerships and collaborations with clients seeking innovative biological solutions.
What is the highest forecasted price for DNA Ginkgo Bioworks Holdings Inc.?
The highest price target for DNA is $12.00 from at , which represents a 39.9% increase from the current price of $8.58.
What is the lowest forecasted price for DNA Ginkgo Bioworks Holdings Inc.?
The lowest price target for DNA is $6.00 from Gaurav Goparaju at Berenberg, which represents a -30.1% decrease from the current price of $8.58.
What is the overall DNA consensus from analysts for Ginkgo Bioworks Holdings Inc.?
The overall analyst consensus for DNA is bearish. Out of 11 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 3 as Sell, with a median price target of $9.00.
How accurate are DNA stock price projections?
Stock price projections, including those for Ginkgo Bioworks Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 2:52 AM UTC